Q3 2026 Financial & Operational Highlights
- Revenue: Reached $3.05 billion, up 22% year-over-year and ahead of the expected $2.91 billion.
- EPS of $3.00 per share.
- Repurchased 7.8 million shares ($2.94 billion) during the quarter; cash and investments stood at approximately $6.8 billion.
- Worldwide procedures (da Vinci and Ion combined) grew approximately 15% compared with the third quarter of 2025. Da Vinci procedures grew approximately 14%, and Ion procedures grew approximately 31%.
You're not a member! Trial today
